Advertisement
Advertisement

ACIU

ACIU logo

AC Immune SA

3.07
USD
Sponsored
-0.27
-8.17%
Feb 04, 16:00 UTC -5
Closed
exchange

After-Market

3.07

0.00
+0.10%

ACIU Earnings Reports

Positive Surprise Ratio

ACIU beat 21 of 36 last estimates.

58%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.25M
/
-$0.16
Implied change from Q3 25 (Revenue/ EPS)
+33.23%
/
--
Implied change from Q4 24 (Revenue/ EPS)
+10.03%
/
--

AC Immune SA earnings per share and revenue

On Nov 04, 2025, ACIU reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.19 USD, resulting in a 17.95% surprise. Revenue reached 939.00 thousand, compared to an expected 829.55 thousand, with a 13.19% difference. The market reacted with a +3.77% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 1.25 million USD, implying an increase of 0.00% EPS, and increase of 33.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
logo
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
logo
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
logo
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
For Q3 2025, AC Immune SA reported EPS of -$0.16, beating estimates by 17.95%, and revenue of $939.00K, 13.19% above expectations.
The stock price moved up 3.77%, changed from $3.18 before the earnings release to $3.30 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 5 analysts, AC Immune SA is expected to report EPS of -$0.16 and revenue of $1.25M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement